Format

Send to

Choose Destination
J Oncol Pract. 2015 Mar;11(2):e255-62. doi: 10.1200/JOP.2014.001842.

Administration of oral chemotherapy: results from three rounds of the quality oncology practice initiative.

Author information

1
Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute, Boston, MA; American Society of Clinical Oncology, Alexandria, VA; Michigan Oncology Quality Consortium, Ann Arbor, MI; and Stanford Cancer Institute, Stanford, CA jzerillo@bidmc.harvard.edu.
2
Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute, Boston, MA; American Society of Clinical Oncology, Alexandria, VA; Michigan Oncology Quality Consortium, Ann Arbor, MI; and Stanford Cancer Institute, Stanford, CA.

Abstract

PURPOSE:

Although use of oral chemotherapy is becoming more prevalent, little is known about the quality of care that patients receive when these agents are prescribed. Moreover, few practice-level systems are in place to ensure safe management of oral chemotherapy in the vulnerable population of patients with cancer.

METHODS:

We analyzed results from 155 practices that were voluntarily participating in the American Society of Clinical Oncology Quality Oncology Practice Initiative (QOPI) program on 17 test measures of oral chemotherapy administration and management in at least one of three collection periods: spring or fall of 2012, or spring of 2013. The 17 test measures cover three domains: treatment plan documentation, patient education, and adherence/toxicity monitoring. We defined composite scores for each of the three domains. We analyzed the composite scores by secular trend and tested the difference in composite scores for the three domains. Additionally, we tested change in scores over time among practices that participated at least twice.

RESULTS:

The majority of data was provided by QOPI-certified practices. Overall, mean practice composite scores ranged from 66% to 68% for treatment plan documentation, 51% to 57% for patient education, and 75% to 81% for adherence/toxicity monitoring. Composite scores for practices that participated more than once did not improve significantly.

CONCLUSION:

The collection of oral chemotherapy test measure data is feasible. Composite scores for treatment plan documentation and patient education were not only lower, but had greater variability compared with adherence/toxicity monitoring. Improvement opportunities exist for patients who are prescribed oral chemotherapy.

PMID:
25784581
DOI:
10.1200/JOP.2014.001842
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center